Overview
Binds to tubulin and microtubule-associated proteins, reducing tau hyperphosphorylation and preserving axonal transport.
Proposed mechanism
Davunetide is a synthetic octapeptide (NAPVSIPQ) derived from activity-dependent neuroprotective protein (ADNP), that interacts with microtubule-associated proteins to stabilize tubulin and prevent tau aggregation.
What the evidence supports
Evidence rests primarily on self-reported experience. Controlled studies are lacking.
Graded Anecdotal
Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Davunetide AL-108
· DOI:10.1016/j.nbd.2008.12.004 · 2009
- [2]
PSP trial davunetide
· DOI:10.1016/S1474-4422(14)70038-6 · 2014
- [3]
Davunetide AL-108 (2009)
· · 0
- [4]
PSP trial davunetide (2014)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.